Angiotensin News and Research

RSS
Angiotensin is an oligopeptide in the blood that causes vasoconstriction, increased blood pressure, and release of aldosterone from the adrenal cortex. It is a powerful dipsogen. It is derived from the precursor molecule angiotensinogen, a serum globulin produced in the liver. It plays an important role in the renin-angiotensin system.
Researchers identify how obese people become salt sensitive, hypertensive

Researchers identify how obese people become salt sensitive, hypertensive

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

Relypsa commences enrollment for RLY5016 Phase 2 study in heart failure patients with chronic kidney disease

ARBs may be linked with increased risk of developing cancer: US scientists

ARBs may be linked with increased risk of developing cancer: US scientists

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

ARBs increase risk of cancer: Study

ARBs increase risk of cancer: Study

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Telmisartan reduces hypertension, cardiovascular risk in ACE-intolerant patients: Boehringer Ingelheim

Trevena's scientists present research data on GPCR biased ligands at two scientific conferences

Trevena's scientists present research data on GPCR biased ligands at two scientific conferences

DermaGenoma releases CelluliteDX Genetic Test for women

DermaGenoma releases CelluliteDX Genetic Test for women

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

POZEN receives milestone payment from AstraZeneca for FDA approval of VIMOVO

Derma Sciences first-quarter net sales up 23% to $12,844,382

Derma Sciences first-quarter net sales up 23% to $12,844,382

Derma Sciences adds XTRASORB Foam dressing to advanced wound care product portfolio

Derma Sciences adds XTRASORB Foam dressing to advanced wound care product portfolio

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

TGRD presents positive results from Phase 3 studies of azilsartan medoxomil for lowering SBP at 25th ASH

Majority of patients who appear healthy may be at risk for cardiovascular disease

Majority of patients who appear healthy may be at risk for cardiovascular disease

VIMOVO delayed-release tablets receive FDA approval

VIMOVO delayed-release tablets receive FDA approval

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Takeda announces submission of azilsartan medoxomil NDA for hypertension to FDA

Study suggests potential ingredient in rice for prevention of cardiovascular diseases

Study suggests potential ingredient in rice for prevention of cardiovascular diseases

Factors of hormone metabolism may make African-Americans more susceptible: Study

Factors of hormone metabolism may make African-Americans more susceptible: Study

Trevena commences Phase I trial of TRV120027 biased ligand for acute decompensated heart failure

Trevena commences Phase I trial of TRV120027 biased ligand for acute decompensated heart failure

Derma Sciences reports 69% increase in Advanced Wound Care sales for fourth-quarter 2009

Derma Sciences reports 69% increase in Advanced Wound Care sales for fourth-quarter 2009

Study: Automatic reporting of estimated GFR may result in unnecessary referrals by physicians

Study: Automatic reporting of estimated GFR may result in unnecessary referrals by physicians

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.